News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to research presented at the annual American Society of Hematology annual meeting in San Francisco.

Tags: ChildhoodCancer, Survivorship, Leukemia

  • Findings by Dana-Farber scientists and others show the disarray in the on-off mechanism – known as methylation – is one of the defining characteristics of cancer and helps tumors adapt to changing circumstances.

Tags: BasicResearch, Genomics

  • A study led by Dana-Farber investigators found that a phase 1 trial of an immune checkpoint blocker found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation.

Tags: MultipleMyeloma, Leukemia, Immunotherapy

  • Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

Tags: Genomics, LungCancer

  • Researchers report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand.

Tags: chemotherapy, StemCellTransplant

  • Dana-Farber and colleagues report that an oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) in a phase 2 clinical trial.

Tags: Leukemia

  • Dana-Farber researchers report that multiple myeloma is driven to spread by a subset of the myeloma cells within a patient’s body, and that attacking those specific subsets with targeted drugs may be better targets for therapy.

Tags: BasicResearch, MultipleMyeloma

  • Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.

Tags: Lymphoma, Immunotherapy

  • The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study by researchers at Dana-Farber Cancer.

Tags: BasicResearch, MultipleMyeloma

  • The Leapfrog Group has named Dana-Farber Cancer Institute to its annual list of Top Hospitals for the first time.

Tags: Honors, PatientSafety

Showing 11-20 of 565 items